NASDAQ Markets
· Aug 26, 2025 7:41 AM EDT
Not market news
EU Approves Gilead's Twice-Yearly Lenacapavir For HIV Prevention
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the European Commission has granted marketing authorization for lenacapavir for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
